To include your compound in the COVID-19 Resource Center, submit it here.

Alexion announces pipeline restructuring

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) restructured its pipeline to focus on its core complement inhibitor franchise and its approved rare disease products, dropping early stage rare disease partnerships with Moderna Therapeutics Inc.

Read the full 311 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE